Table 4 Targeted treatment in luminal-B breast cancer
Pathway | Agent | Supplier | Class | Phase | Study design | Eligible population |
|---|---|---|---|---|---|---|
IGF | BMS-754807 | BristolMyersSquibb | IGF-1R/IR TKI | II | BMS-754807 ± letrozole | ER-positive locally advanced/metastatic breast cancer, progressed on prior nonsteroidal aromatase inhibitors |
| Â | Cixutumumab | ImClone | IGF-1R mAb | I/II | Cixutumumab and temsirolimus | Locally advanced/metastatic breast cancer progressed on one or two chemotherapy lines |
| Â | MK-0646 | Merck | IGF-1R mAb | I/II | MK-0646 and fulvestrant and dasatinib | Locally advanced/metastatic ER-positive breast cancer with no previous treatment in metastatic setting |
| Â | Dalotuzumab | Merck | IGF-1R mAb | II | Dalotuzumab and ridaforolimus versus standard care | ER-positive locally advanced/metastatic breast cancer, progressed on at least one line of endocrine therapy |
|  | OSI-906 | OSI | IGF-1R/IR TKI | II | OSI-906 and endocrine therapy ± erlotinib | ER-positive metastatic breast cancer, treated with ≤4 chemotherapy regimens |
| Â | CP-758171 | Pfizer | IGF-1R TKI | I | CP-758171 for two cycles prior to curative surgery | Operable early breast cancer |
FGF | TKI-258 | Novartis | FGFR/VEGFR TKI | II | TKI-259 single agent | HER2-negative, FGFR1 amplified and FGFR1 normal metastatic breast cancer |
|  | AZD-4547 | Astra Zeneca | FGFR TKI | II | Exemestane ± AZD-4547 | ER-positive locally advanced/metastatic breast cancer with high levels of FGFR1 expression |
PI3K/AKT | MK-2206 | Merck | AKT inhibitor | II | MK-2206 single agent | Metastatic breast cancer with PIK3CA mutation and/or PTEN loss, progressed on at least one line of therapy |
| Â | MK-2206 | Merck | AKT inhibitor | II | MK-2206 and endocrine therapy | ER-positive metastatic breast cancer progressed on endocrine therapy |
| Â | XL-147 | Exelixis | PI3K inhibitor | II | XL-147 and letrozole | ER-positive metastatic breast cancer refractory to nonsteroidal aromatase inhibitors |
| Â | XL-765 | Exelixis | PI3K/mTOR inhibitor | II | XL-765 and letrozole | ER-positive metastatic breast cancer refractory to nonsteroidal aromatase inhibitors |